Takeda to Acquire Nycomed - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Takeda to Acquire Nycomed

ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical has agreed to acquire Nycomed, a Swiss pharmaceutical company for €9.6 billion ($13.7 billion), excluding Nycomed’s US dermatology business. The deal is intended to increase Takeda’s presence in European and emerging markets.

Nycomed had overall sales of nearly €3.2 billion ($4.5 billion) in fiscal year 2010, and sales of €2.8 billion ($3.9 billion) when excluding its US dermatology business. It is a privately held Zurich-based pharmaceutical company with prescription and over-the-counter products. The acquisition includes the roflumilast franchise, a treatment for chronic obstructive pulmonary disease, which Takeda expects will be a “major source of revenue growth,” according to a May 19, 2011, Takeda press release. Overall, Takeda expects the acquisition to increase its annual revenue by 30%.

The boards of directors of Takeda and Nycomed have agreed to the transaction, as have the shareholders of Nycomed. The deal is expected to close within 90 to 120 days, subject to antitrust approval. Upon closing, Nycomed will become a subsidiary of Takeda. Nycomed is currently owned by the private-equity group Nordic Capital and other investors.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here